FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...
Medscape3d
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
pulmonologyadvisor4d
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome Warning
The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV] vaccine) and Arexvy ® (RSV vaccine, adjuvanted) has been updated to include a new warning regarding the risk of ...
pulmonologyadvisor1d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
healthday on MSN11d
FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing informa ...
Renal & Urology News10d
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome Warning
According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...
Mena FN4d
Abrysvo Or Arexvy Global Market Report 2025: Market Size, Growth Trends, Key Players, And Future Market Forecasts
The abrysvo or arexvy market's growth is expected to be significantly driven by the increasing prevalence of respiratory syncytial virus RSV infections. RSV infections primarily affect the ...
cidrap.umn1d
Real-world study: RSV vaccine 78% to 80% effective against infection, severe illness in older US veterans
The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...